氣喘 Maintenance treatment of asthma as prophylactic therapy in patients >1 year of age

(Not indicated for relief of acute bronchospasm)

Corticosteroid, Inhalant (Oral)

Absorption:
Absorbed systemically primarily via lungs; minimal GI absorption (<1%) due to presystemic metabolism
Distribution: 1. 4.2 L/kg
2. Protein binding: >99%
Metabolism:
Hepatic via CYP3A4 to 17β-carboxylic acid (negligible activity)
Excretion:
1. Feces (as parent drug and metabolites)
2. Urine (<5% as metabolites)
Pharmacodynamics:
1. Bioavailability: 13.9%
2. Half-life elimination: ~11.2 hours (terminal half-life)
3. Time to peak, plasma: 0.5 to 1 hour
4. Onset of action: Maximal benefit may take 1 to 2 weeks or longer

1. Hypersensitivity to fluticasone or any component of the formulation.
2. Severe hypersensitivity to milk proteins or lactose.
3. Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures.

Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy; use with caution.

It is not known if sufficient quantities of fluticasone are absorbed following inhalation to produce detectable amounts in breast milk.

Fatigue, malaise, headache, oral candidiasis, arthralgia, musculoskeletal pain, sinus infection, sinusitis, upper respiratory tract infection, throat irritation, nasal congestion, rhinitis

Adult and children ≥16 years of age:
1. Mild asthma: 100 to 250 mcg twice daily
2. Moderate asthma: 250 to 500 mcg twice daily
3. Severe asthma: 500 mcg twice daily; may increase up to 1,000 mcg twice daily in very severe patients

Children 4-16 years:
50 to 200 mcg twice daily; dose may be initiated as 50 or 100 mcg twice daily
Children 1-4 years:
50 to 100 mcg twice daily

No dosage adjustment necessary.

No dosage adjustment necessary.